CHECKPOINT THER. DL-0001 Market Cap ($325.84 Million)
Market Cap & Net Worth: CHECKPOINT THER. DL-0001 (CZTA)
CHECKPOINT THER. DL-0001 market cap. CHECKPOINT THER. DL-0001 (F:CZTA) has a market capitalization of $325.84 Million (€278.71 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #14153 globally and #1444 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CHECKPOINT THER. DL-0001's stock price €3.76 by its total outstanding shares 86320000 (86.32 Million).
CHECKPOINT THER. DL-0001 Market Cap History (2020–2025)
CHECKPOINT THER. DL-0001 market cap history from 2020 to 2025. Data shows growth from $207.94 Million to $378.94 Million (14.49% CAGR). Check current stock price of CHECKPOINT THER. DL-0001 for real-time trading data and today's change.
CHECKPOINT THER. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CHECKPOINT THER. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CZTA by Market Capitalization
Companies near CHECKPOINT THER. DL-0001 in the global market cap rankings as of November 4, 2026.
Key companies related to CHECKPOINT THER. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of CHECKPOINT THER. DL-0001 (2020–2025)
Market capitalization of CHECKPOINT THER. DL-0001 from 2020 to today. Between 2020 and today, CHECKPOINT THER. DL-0001's market cap moved from $207.94 Million to $ 378.94 Million, with a yearly change of 14.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €378.94 Million | +15.01% |
| 2024 | €329.49 Million | +60.05% |
| 2023 | €205.87 Million | -46.57% |
| 2022 | €385.30 Million | +53.95% |
| 2021 | €250.27 Million | +20.36% |
| 2020 | €207.94 Million | -- |
End of Day Market Cap According to Different Sources
On May 28th, 2026 the market cap of CHECKPOINT THER. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $325.84 Million USD |
| MoneyControl | $325.84 Million USD |
| MarketWatch | $325.84 Million USD |
| marketcap.company | $325.84 Million USD |
| Reuters | $325.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CHECKPOINT THER. DL-0001
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more